The linked FDA records identify Siemens Medical Solutions USA, Inc. as the applicant on two 510(k) clearances decided in September 2026. The filings span two advisory committees and two distinct device types: radiology software for CT brain quantification and a cardiovascular intravascular ultrasound catheter. The two records carry a substantially equivalent decision, and both list a summary as the statement or summary type. The collection counts below describe the supplied filings as of the snapshot date, not total company sales, total portfolio or safety performance. [1][2]
Radiology software: syngo.CT Brain Quantification
K260055 covers syngo.CT Brain Quantification under product code QIH, regulation number 892.2050, device name Automated Radiological Image Processing Software, Class II, in the radiology advisory committee. The record lists a Traditional clearance type, no third-party review, and a decision date of September 25, 2026, with the application received January 8, 2026. The applicant address on the record is 810 Innovation Dr., Knoxville, Tennessee. [1]
The same record lists the device as substantially equivalent and notes a summary rather than a full statement. The openFDA fields attached to the record describe the device class as 2 and the medical specialty as Radiology. The record does not describe clinical performance, indications wording or commercial availability. [1]
Cardiovascular device: ACUNAV Luxera 4D ICE Catheter
K261696 covers the ACUNAV Luxera 4D ICE Catheter under product code OBJ, regulation number 870.1200, device name Catheter, Ultrasound, Intravascular, Class II, in the cardiovascular advisory committee. The record lists a Special clearance type, no third-party review, and a decision date of September 10, 2026, with the application received May 22, 2026. The applicant address on the record is 22010 S. E. 51st St., Issaquah, Washington. [2]
The FDA clearance letter for K261696 names the trade device as ACUNAV Luxera 4D ICE Catheter, regulation name Diagnostic Intravascular Catheter, regulatory class Class II, product code OBJ, dated and received August 11, 2026, and addressed to a senior regulatory affairs professional at the Issaquah address. The letter states the firm's opinion that diagnostic ultrasound has accumulated a long history of safe and effective performance; that statement is attributed to the firm, not to FDA. [5]
Related syngo.CT filings in the public documents
Separate FDA documents in the public documents describe other syngo.CT submissions by the same applicant. K241757 covers syngo.CT Dual Energy under regulation 892.1750, product code JAK, Class II, dated December 5, 2024 and received December 5, 2024, with a January 3, 2025 letter addressed to a regulatory affairs professional in Knoxville. K251805 covers the same trade device under the same regulation and product code, dated August 8, 2025 and received September 12, 2025, with an October 15, 2025 letter. [8][9]
K243145 covers syngo.CT LVO Detection under regulation 892.2080, radiological computer aided triage and notification software, product code QAS, Class II, dated and received March 4, 2025, with an April 10, 2025 letter. The K251805 determination states that syngo.CT Dual Energy has the same intended use and similar indication for use as its predicate device and no changes in fundamental scientific technology. These documents are not part of the two-record sample described above. [10][9]
Recall record and scope limits
A Class 2 device recall record in the public documents covers SOMATOM X.ceed, initiated by the firm December 19, 2025, posted February 3, 2026, recall number Z-1239-2026, with status listed as open and classified. The record links to 510(k) entries with product code JAK. The supplied portfolio sample contains no recall rows, so the recall record is not part of that sample. [7]
The supplied collection holds two linked 510(k) records, both with a substantially equivalent decision; the smaller record sample also holds two records with the same decision. These counts describe the supplied filings as of the snapshot date and are not measures of total company portfolio, sales or safety performance. Ownership, headquarters, customers and commercial availability are not established by these records. [1][2]






